Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...
Hosted on MSN21h
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & MoreSanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...
Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback